Penn Medicine’s Cancer Breakthrough
Just Approved: First-of-its-Kind Gene Therapy
Penn Medicine created the revolutionary gene therapy known as CAR-T cell. This is a type of immunotherapy that genetically alters a patient’s own immune cells to target and destroy their cancer.
CAR-T cell therapy is currently FDA-approved for:
- Children and young adults up to age 25 with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL)
- Adults with diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin lymphoma
We have ongoing CAR-T clinical trials available for other types of blood and solid tumor cancers.
Is CAR-T Right For You?
Get a call back from a nurse today